Gene-Chemical Interaction Annotations Click to see Annotation Detail View
Term | Qualifier | Evidence | With | Reference | Notes | Source | Original Reference(s) | (1->4)-beta-D-glucan | multiple interactions | ISO | Zfp385b (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of ZFP385B mRNA | CTD | PMID:36331819 | 1,2-dichloroethane | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | ethylene dichloride results in decreased expression of ZFP385B mRNA | CTD | PMID:28960355 | 1,2-dimethylhydrazine | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | 1 and 2-Dimethylhydrazine results in decreased expression of ZFP385B mRNA | CTD | PMID:22206623 | 17beta-estradiol | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [Estradiol co-treated with TGFB1 protein] results in increased expression of ZNF385B mRNA | CTD | PMID:30165855 | 17beta-estradiol | decreases expression | EXP | | 6480464 | Estradiol results in decreased expression of ZFP385B mRNA | CTD | PMID:32145629 | 17beta-hydroxy-5alpha-androstan-3-one | increases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Dihydrotestosterone results in increased expression of ZNF385B mRNA | CTD | PMID:29581250 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ZFP385B mRNA | CTD | PMID:19770486 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ZFP385B mRNA | CTD | PMID:32109520 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | Zfp385b (Mus musculus) | 6480464 | Tetrachlorodibenzodioxin affects the expression of ZFP385B mRNA | CTD | PMID:28922406 | 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of ZNF385B mRNA | CTD | PMID:20106945 and PMID:21632981 | 2,3,7,8-tetrachlorodibenzodioxine | affects expression | EXP | | 6480464 | Tetrachlorodibenzodioxin affects the expression of ZFP385B mRNA | CTD | PMID:22298810 | 2,3,7,8-Tetrachlorodibenzofuran | decreases expression | EXP | | 6480464 | 2 more ... | CTD | PMID:32109520 | 4,4'-sulfonyldiphenol | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | bisphenol S results in decreased expression of ZFP385B mRNA | CTD | PMID:30951980 | 4,4'-sulfonyldiphenol | increases methylation | ISO | Zfp385b (Mus musculus) | 6480464 | bisphenol S results in increased methylation of ZFP385B exon | CTD | PMID:33297965 | 4-hydroxyphenyl retinamide | increases expression | ISO | Zfp385b (Mus musculus) | 6480464 | Fenretinide results in increased expression of ZNF385B mRNA | CTD | PMID:28973697 | 5-aza-2'-deoxycytidine | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | Decitabine inhibits the reaction [Smoke results in decreased expression of ZNF385B mRNA] | CTD | PMID:21095227 | 6-propyl-2-thiouracil | decreases expression | EXP | | 6480464 | Propylthiouracil results in decreased expression of ZFP385B mRNA | CTD | PMID:24780913 | aflatoxin B1 | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased expression of ZNF385B mRNA | CTD | PMID:22100608 | aflatoxin B1 | decreases methylation | ISO | ZNF385B (Homo sapiens) | 6480464 | Aflatoxin B1 results in decreased methylation of ZNF385B gene | CTD | PMID:27153756 | all-trans-retinoic acid | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Tretinoin results in decreased expression of ZNF385B mRNA | CTD | PMID:23724009 | arsane | affects methylation | ISO | ZNF385B (Homo sapiens) | 6480464 | Arsenic affects the methylation of ZNF385B gene | CTD | PMID:25304211 | arsenic atom | affects methylation | ISO | ZNF385B (Homo sapiens) | 6480464 | Arsenic affects the methylation of ZNF385B gene | CTD | PMID:25304211 | azathioprine | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Azathioprine results in decreased expression of ZNF385B mRNA | CTD | PMID:22623647 | benzo[a]pyrene | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased expression of ZFP385B mRNA | CTD | PMID:19770486 | benzo[a]pyrene | increases methylation | ISO | ZNF385B (Homo sapiens) | 6480464 | Benzo(a)pyrene results in increased methylation of ZNF385B exon and Benzo(a)pyrene results in increased methylation of ZNF385B promoter | CTD | PMID:27901495 | benzo[a]pyrene | decreases methylation | ISO | ZNF385B (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased methylation of ZNF385B 5' UTR | CTD | PMID:27901495 | benzo[a]pyrene | decreases methylation | ISO | Zfp385b (Mus musculus) | 6480464 | Benzo(a)pyrene results in decreased methylation of ZFP385B intron | CTD | PMID:27901495 | benzo[a]pyrene | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Benzo(a)pyrene results in decreased expression of ZNF385B mRNA | CTD | PMID:20106945 and PMID:21632981 | bisphenol A | decreases expression | EXP | | 6480464 | bisphenol A results in decreased expression of ZFP385B mRNA and bisphenol A results in decreased expression of ZNF385B mRNA | CTD | PMID:25181051 more ... | bisphenol A | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | bisphenol A results in decreased expression of ZFP385B mRNA | CTD | PMID:32156529 | bisphenol A | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of ZNF385B gene | CTD | PMID:31601247 | bisphenol A | affects expression | ISO | Zfp385b (Mus musculus) | 6480464 | bisphenol A affects the expression of ZFP385B mRNA | CTD | PMID:30951980 | bisphenol A | increases methylation | EXP | | 6480464 | bisphenol A results in increased methylation of ZFP385B gene | CTD | PMID:28505145 | bisphenol F | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | bisphenol F results in decreased expression of ZFP385B mRNA | CTD | PMID:30951980 | bromobenzene | decreases expression | EXP | | 6480464 | bromobenzene results in decreased expression of ZFP385B mRNA | CTD | PMID:32479839 | caffeine | affects phosphorylation | ISO | ZNF385B (Homo sapiens) | 6480464 | Caffeine affects the phosphorylation of ZNF385B protein | CTD | PMID:35688186 | carbamazepine | affects expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Carbamazepine affects the expression of ZNF385B mRNA | CTD | PMID:25979313 | carbon nanotube | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | Nanotubes and Carbon results in decreased expression of ZFP385B mRNA | CTD | PMID:25620056 | CGP 52608 | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | CGP 52608 promotes the reaction [RORA protein binds to ZNF385B gene] | CTD | PMID:28238834 | choline | multiple interactions | ISO | Zfp385b (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of ZFP385B mRNA | CTD | PMID:20938992 | copper(II) sulfate | increases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Copper Sulfate results in increased expression of ZNF385B mRNA | CTD | PMID:19549813 | coumestrol | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [Coumestrol co-treated with resveratrol] results in increased expression of ZNF385B mRNA | CTD | PMID:19167446 | cyclosporin A | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Cyclosporine results in decreased expression of ZNF385B mRNA | CTD | PMID:20106945 and PMID:25562108 | dibenz[a,h]anthracene | increases expression | ISO | Zfp385b (Mus musculus) | 6480464 | 1 more ... | CTD | PMID:26377693 | dicrotophos | increases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | dicrotophos results in increased expression of ZNF385B mRNA | CTD | PMID:28302478 | dorsomorphin | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | endosulfan | increases expression | EXP | | 6480464 | Endosulfan results in increased expression of ZFP385B mRNA | CTD | PMID:29391264 | entinostat | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | entinostat results in decreased expression of ZNF385B mRNA | CTD | PMID:26272509 | entinostat | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA | CTD | PMID:27188386 | epoxiconazole | affects expression | ISO | Zfp385b (Mus musculus) | 6480464 | epoxiconazole affects the expression of ZFP385B mRNA | CTD | PMID:35436446 | flutamide | increases expression | EXP | | 6480464 | Flutamide results in increased expression of ZFP385B mRNA | CTD | PMID:24136188 | folic acid | multiple interactions | ISO | Zfp385b (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of ZFP385B mRNA | CTD | PMID:20938992 | fulvestrant | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [bisphenol A co-treated with Fulvestrant] results in increased methylation of ZNF385B gene | CTD | PMID:31601247 | fulvestrant | decreases methylation | ISO | ZNF385B (Homo sapiens) | 6480464 | Fulvestrant results in decreased methylation of ZNF385B gene | CTD | PMID:31601247 | gentamycin | decreases expression | EXP | | 6480464 | Gentamicins results in decreased expression of ZFP385B mRNA | CTD | PMID:33387578 | L-methionine | multiple interactions | ISO | Zfp385b (Mus musculus) | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of ZFP385B mRNA | CTD | PMID:20938992 | lipopolysaccharide | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of ZNF385B mRNA | CTD | PMID:35811015 | lipopolysaccharide | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Lipopolysaccharides results in decreased expression of ZNF385B mRNA | CTD | PMID:35811015 | mercury dibromide | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | mercuric bromide results in decreased expression of ZNF385B mRNA | CTD | PMID:26272509 | mercury dibromide | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA | CTD | PMID:27188386 | methidathion | increases expression | ISO | Zfp385b (Mus musculus) | 6480464 | methidathion results in increased expression of ZFP385B mRNA | CTD | PMID:34813904 | methoxychlor | affects methylation | EXP | | 6480464 | Methoxychlor affects the methylation of ZFP385B gene | CTD | PMID:35440735 | methylmercury chloride | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | methylmercuric chloride results in decreased expression of ZNF385B mRNA | CTD | PMID:28001369 | nickel atom | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Nickel results in decreased expression of ZNF385B mRNA | CTD | PMID:24768652 and PMID:25583101 | p-chloromercuribenzoic acid | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | p-Chloromercuribenzoic Acid results in decreased expression of ZNF385B mRNA | CTD | PMID:26272509 | p-chloromercuribenzoic acid | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA | CTD | PMID:27188386 | panobinostat | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA | CTD | PMID:27188386 | panobinostat | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | panobinostat results in decreased expression of ZNF385B mRNA | CTD | PMID:26272509 | paracetamol | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Acetaminophen results in decreased expression of ZNF385B mRNA | CTD | PMID:29067470 | parathion | increases expression | ISO | Zfp385b (Mus musculus) | 6480464 | Parathion results in increased expression of ZFP385B mRNA | CTD | PMID:34813904 | perfluorohexanesulfonic acid | increases expression | ISO | Zfp385b (Mus musculus) | 6480464 | perfluorohexanesulfonic acid results in increased expression of ZFP385B mRNA | CTD | PMID:37995155 | perfluorooctane-1-sulfonic acid | multiple interactions | ISO | Zfp385b (Mus musculus) | 6480464 | [perfluorooctane sulfonic acid co-treated with Cellulose] results in increased expression of ZFP385B mRNA | CTD | PMID:36331819 | phenobarbital | increases expression | ISO | Zfp385b (Mus musculus) | 6480464 | Phenobarbital results in increased expression of ZFP385B mRNA | CTD | PMID:19270015 | phenobarbital | affects expression | ISO | Zfp385b (Mus musculus) | 6480464 | Phenobarbital affects the expression of ZFP385B mRNA | CTD | PMID:23091169 | phenylmercury acetate | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Phenylmercuric Acetate results in decreased expression of ZNF385B mRNA | CTD | PMID:26272509 | phenylmercury acetate | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA | CTD | PMID:27188386 | pirinixic acid | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | pirinixic acid results in decreased expression of ZFP385B mRNA | CTD | PMID:23811191 | quercetin | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Quercetin results in decreased expression of ZNF385B mRNA | CTD | PMID:21632981 | resveratrol | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [Coumestrol co-treated with Resveratrol] results in increased expression of ZNF385B mRNA and [Plant Extracts co-treated with Resveratrol] results in decreased expression of ZNF385B mRNA | CTD | PMID:19167446 and PMID:23557933 | rotenone | increases expression | EXP | | 6480464 | Rotenone results in increased expression of ZFP385B mRNA | CTD | PMID:28374803 | S-(1,2-dichlorovinyl)-L-cysteine | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of ZNF385B mRNA | CTD | PMID:35811015 | SB 431542 | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... | CTD | PMID:27188386 | serpentine asbestos | increases methylation | ISO | ZNF385B (Homo sapiens) | 6480464 | Asbestos and Serpentine results in increased methylation of ZNF385B 5' UTR | CTD | PMID:29523930 | sodium arsenite | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | sodium arsenite results in decreased expression of ZFP385B mRNA | CTD | PMID:37682722 | temozolomide | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Temozolomide results in decreased expression of ZNF385B mRNA | CTD | PMID:31758290 | tetrachloromethane | decreases expression | ISO | Zfp385b (Mus musculus) | 6480464 | Carbon Tetrachloride results in decreased expression of ZFP385B mRNA | CTD | PMID:31919559 | thioacetamide | decreases expression | EXP | | 6480464 | Thioacetamide results in decreased expression of ZFP385B mRNA | CTD | PMID:34492290 | trichloroethene | increases expression | EXP | | 6480464 | Trichloroethylene results in increased expression of ZFP385B mRNA | CTD | PMID:33387578 | trichostatin A | increases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | trichostatin A results in increased expression of ZNF385B mRNA | CTD | PMID:24935251 | trichostatin A | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA | CTD | PMID:27188386 | trichostatin A | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | trichostatin A results in decreased expression of ZNF385B mRNA | CTD | PMID:24935251 and PMID:26272509 | triclosan | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Triclosan results in decreased expression of ZNF385B mRNA | CTD | PMID:30510588 | tris(2-butoxyethyl) phosphate | affects expression | ISO | ZNF385B (Homo sapiens) | 6480464 | tris(2-butoxyethyl) phosphate affects the expression of ZNF385B mRNA | CTD | PMID:29024780 | urethane | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Urethane results in decreased expression of ZNF385B mRNA | CTD | PMID:28818685 | valproic acid | affects expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Valproic Acid affects the expression of ZNF385B mRNA | CTD | PMID:25979313 | valproic acid | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA | CTD | PMID:27188386 | valproic acid | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Valproic Acid results in decreased expression of ZNF385B mRNA | CTD | PMID:23179753 more ... | valproic acid | decreases methylation | ISO | ZNF385B (Homo sapiens) | 6480464 | Valproic Acid results in decreased methylation of ZNF385B gene | CTD | PMID:29154799 | valproic acid | increases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | Valproic Acid results in increased expression of ZNF385B mRNA | CTD | PMID:24935251 | vancomycin | increases expression | ISO | Zfp385b (Mus musculus) | 6480464 | Vancomycin results in increased expression of ZFP385B mRNA | CTD | PMID:18930951 | vorinostat | multiple interactions | ISO | ZNF385B (Homo sapiens) | 6480464 | [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZNF385B mRNA | CTD | PMID:27188386 | vorinostat | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | vorinostat results in decreased expression of ZNF385B mRNA | CTD | PMID:26272509 | vorinostat | increases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | vorinostat results in increased expression of ZNF385B mRNA | CTD | PMID:27188386 | zoledronic acid | decreases expression | ISO | ZNF385B (Homo sapiens) | 6480464 | zoledronic acid results in decreased expression of ZNF385B mRNA | CTD | PMID:24714768 | |